

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 May 2021 (06.05.2021)(10) International Publication Number
WO 2021/086833 A8

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/522 (2006.01)
C07D 498/04 (2006.01) A61P 35/00 (2006.01)

33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US).
SLOMAN, David, L.; 33 Avenue Louis Pasteur, Boston,
MA 02115-5727 (US).

(21) International Application Number:

PCT/US2020/057496

(74) Agent: **HOLOWACZ, Elizabeth, F.** et al.; Venable LLP,
1290 Avenue of The Americas, New York, NY 10104-3800
(US).

(22) International Filing Date:

27 October 2020 (27.10.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/926,879 28 October 2019 (28.10.2019) US
63/030,014 26 May 2020 (26.05.2020) US


(71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065
(US).

(72) Inventors: **BHARATHAN, Indu**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **GATHIAKA, Symon**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **GRAHAM, Thomas, H.**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **HAN, Yongxin**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **HENDERSON, Timothy**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **HENNESSY, Elisabeth**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **MA, Xiaoshen**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **OTTE, Ryan**; 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **PALANI, Anandan**;

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT



(I)

(57) Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W^1 , W^2 , Y, Z, M, L, C^y , C^z , R^1 , R^2 , R^3 , R^4 , R^{2a} , R^y , R^z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

14 July 2022 (14.07.2022)

(15) Information about Correction:

see Notice of 14 July 2022 (14.07.2022)